SEC Form 4 · accession 0001615219-18-000038
Decoy Therapeutics Inc. · DCOY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John P. McCabe
Officer — Chief Financial Officer
Period of report
Jun 14, 2018
Accepted (ET)
Jun 18, 2018 · 4:14 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001615219
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $1.35 | Jun 14, 2018 | A | 179,848 | A | — | Jun 14, 2028 | Common Stock | 179,848 | 179,848 | D |
Explanation of responses
- F1The stock option will vest in 48 successive equal monthly installments measured from June 14, 2018.